{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:36:07Z","timestamp":1793126167787,"version":"4.5.0"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sotagliflozin is a novel dual sodium\u2010glucose cotransporter inhibitor (SGLTi). At present, the comprehensive assessment of its influence on cardiorenal outcomes in diabetic patients remains inadequate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We retrieved and screened RCTs of sotagliflozin for diabetes from online databases. Primary endpoint was the expanded major adverse cardiovascular and heart failure composite endpoint, comprising cardiovascular death, heart failure hospitalisation, non\u2010fatal myocardial infarction, and non\u2010fatal stroke; secondary endpoint was substantial renal function decline. Pooled effect sizes were calculated as relative risk (RR) and 95% confidence interval (CI). Cochrane RoB 2.0 assessed bias risk. Subgroup, sensitivity, cumulative analyses, and publication bias tests verified result robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After strict screening, 11 high\u2010quality RCT datasets (including 7 peer\u2010reviewed full publications and 4 ClinicalTrials.gov registry records) were ultimately included. Meta\u2010synthesis results demonstrated that sotagliflozin was associated with a reduced risk of the expanded cardiovascular composite endpoint (RR\u2009=\u20090.80, 95% CI [0.75, 0.88],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Regarding the incidence of a substantial decline in renal function, the sotagliflozin group showed a potential protective tendency, but it was not statistically significant (RR\u2009=\u20090.77, 95% CI [0.46, 1.27],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.53). Subgroup analyses revealed that sotagliflozin maintained a highly consistent cardiovascular benefit in patients with type 2 diabetes mellitus, in studies adopting flexible dose titration (200\u2009\u2192\u2009400\u2009mg), and across different follow\u2010up periods. Sensitivity and cumulative analyses confirmed the high robustness of the core findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sotagliflozin provides significant and consistent cardiovascular benefit in patients with diabetes, particularly type 2 diabetes, with good safety. A potential renal protective trend exists. It is an effective treatment for diabetic patients at high cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70876","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:24:41Z","timestamp":1780359881000},"page":"7207-7217","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiorenal Safety and Efficacy of Sotagliflozin: A Stratified Meta\u2010Analysis by Diabetes Type and Dosage"],"prefix":"10.1111","volume":"28","author":[{"given":"Junlei","family":"Liao","sequence":"first","affiliation":[{"name":"Health Management Center of Affiliated Hospital of Northern Sichuan Medical College  Nanchong Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Northern Sichuan Medical College  Nanchong Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-1240","authenticated-orcid":false,"given":"Rongchuan","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Cardiology Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine)  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200436"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569\u2010018\u20100065\u20101"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3702"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14583"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108330"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2023.10.004"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.861"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231211179"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.09.004"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(24)00362\u20100"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1414801"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(23)00128\u20106"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.06.015"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1053"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780070807"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895\u20104356(94)00106\u2010z"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14513"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15019"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18\u20100343"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18\u20100342"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337"},{"key":"e_1_2_11_24_1","unstructured":"\u201cEfficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents (SOTA\u2010INS)\u2014Full\u2010Text View\u2014ClinicalTrials.gov \u201dhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03285594."},{"key":"e_1_2_11_25_1","unstructured":"\u201cEfficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA\u2010EMPA)\u2014Full\u2010Text View\u2014ClinicalTrials.gov \u201dhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03351478."},{"key":"e_1_2_11_26_1","unstructured":"\u201cEfficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin\u2014Full\u2010Text View\u2014ClinicalTrials.gov \u201dhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02926950."},{"key":"e_1_2_11_27_1","unstructured":"\u201cEfficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin\u2014Full\u2010Text View\u2014ClinicalTrials.gov \u201dhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03066830."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010021\u201001366\u20108"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61020202"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010025\u201004374\u2010w"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.109178"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112379"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13645"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106598"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010019\u20100828\u2010y"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010019\u201001146\u20105"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569\u2010020\u201000486\u20100"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557\u2010025\u201007723\u2010z"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102288\u20105\u201013"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00553"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c02225"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069568"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70876","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:17:51Z","timestamp":1793125071000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/dom.70876"],"URL":"https:\/\/doi.org\/10.1111\/dom.70876","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70876\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70876\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70876\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70876\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70876\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2026-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}